Comparison of hyaluronidase-facilitated subcutaneous immunoglobulin 10% pharmacokinetics in pediatric and adult patients with primary immunodeficiency: an analysis of three phase 3 clinical trials
Immunotherapy Advances · 31.12.2025 · 6 (1)
DOI: 10.1093/immadv/ltag022 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunotherapy Advances, online erschienen am 13.10.2026. Verfasst von Zhaoyang Li und 1 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology & Early Clinical Development, Takeda Development Center Americas, Inc., Cambridge, MA, United States. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Development Center Americas, Inc, Takeda Pharmaceuticals International AG.
Abstract (Originalsprache)
Introduction
Facilitated subcutaneous immunoglobulin (fSCIG) 10% is approved for the treatment of primary immunodeficiency (PID) in both pediatric and adult patients. However, it remains unclear whether there is a clinically meaningful difference in the pharmacokinetics (PK) of immunoglobulin G (IgG) between these two populations.
Methods
Serum total IgG concentrations in pediatric and adult patients (aged 3–80 years) with PID from three phase 3 clinical trials of fSCIG 10% were analyzed (NCT00814320, NCT01175213, NCT03277313). Serum total IgG trough concentrations (Ctrough) were compared against the conservative threshold for treatment effectiveness of 7 g/l, and between adult and pediatric patients (aged 2 to <17 years) and pediatric subgroups (2 to <12 years and 12 to <17 years). PK parameters, including steady-state maximum concentration (Cmax), area under the curve during the dosing interval, normalized by week (AUC/week), and apparent clearance normalized for body weight (CL/F/BW), were also compared across age groups.
Results
All age groups effectively achieved mean IgG Ctrough above 7 g/l following fSCIG 10% administration. Total IgG exposures (mean Ctrough, Cmax, and AUC/week) marginally increased with age (all P < 0.05), while there was considerable variability within age groups. However, after total IgG baseline correction, there were no differences in any exposure parameters by age. CL/F/BW remained consistent across studies and age groups. Conclusion fSCIG 10% effectively maintains Ctrough in IgG treatment-experienced patients with PID. The small age-related differences observed in serum total IgG PK are unlikely to be clinically significant and dose adjustments by age alone are not warranted.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Clinical Pharmacology & Early Clinical Development, Takeda Development Center Americas, Inc., Cambridge, MA, United States.
- Clinical Pharmacology, Certara Strategic Consulting, Certara USA, Inc., Radnor, PA, United States.
ORCID-Profile: Zhaoyang Li, Alex Ballesteros-Perez
Förderung
- Takeda Development Center Americas, Inc
- Takeda Pharmaceuticals International AG
Zitieren
APA
Li, Z., & Ballesteros-Perez, A. (2025). Comparison of hyaluronidase-facilitated subcutaneous immunoglobulin 10% pharmacokinetics in pediatric and adult patients with primary immunodeficiency: an analysis of three phase 3 clinical trials. Immunotherapy Advances, 6(1). https://doi.org/10.1093/immadv/ltag022
Vancouver
Li Z, Ballesteros-Perez A. Comparison of hyaluronidase-facilitated subcutaneous immunoglobulin 10% pharmacokinetics in pediatric and adult patients with primary immunodeficiency: an analysis of three phase 3 clinical trials. Immunotherapy Advances. 2025;6(1). doi:10.1093/immadv/ltag022
BibTeX
@article{Li2025,
author = {Li, Zhaoyang and Ballesteros-Perez, Alex},
title = {Comparison of hyaluronidase-facilitated subcutaneous immunoglobulin 10% pharmacokinetics in pediatric and adult patients with primary immunodeficiency: an analysis of three phase 3 clinical trials},
journal = {Immunotherapy Advances},
year = {2025},
volume = {6},
number = {1},
doi = {10.1093/immadv/ltag022}
}
EUVIMED